Brain metastases outcome

• Effect of radiochemotherapy on peripheral immune response in glioblastoma
• Insulin Resistance Increases TNBC Aggressiveness and Brain Metastasis via Adipocyte-derived Exosomes
• Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways
• Prediction of treatment response after stereotactic radiosurgery of brain metastasis using deep learning and radiomics on longitudinal MRI data
• Influence of SLC40A1 on Cytokine Interactions and Immune Infiltration in Glioblastoma
• Long-term outcomes of neuroendoscopic cyst partial resection combined with stereotactic radiotherapy for craniopharyngioma
• Differentially expressed genes associated with high metabolic tumor volume served as diagnostic markers and potential therapeutic targets for pancreatic cancer
• Letter to the Editor: "Imperative for Increased Research into Tumor Treating Fields Therapy for Enhancing Glioblastoma Outcomes"

In a systematic review and meta-analysis of patients with Intracranial metastatic disease in the setting of limited or stable extracranial disease, the limited systemic disease was associated with improved OS and intracranial PFS. Future prospective trials should aim to collect granular information on the extent of extracranial disease to identify drivers of mortality and optimal treatment strategies in patients with brain metastases ¹⁾.

Overall prognosis depends on age, extent and activity of the systemic disease, number of brain metastases and performance status. In about half of the patients, especially those with widespread and uncontrolled systemic malignancy, death is heavily related to extra-neural lesions, and treatment of cerebral disease doesn't significantly improve survival.

In such patients the aim is to improve or stabilize the neurological deficit and maintain quality of life. Corticosteroids and whole brain radiotherapy usually fulfill this purpose. By contrast, patients with a limited number of brain metastases, good performance status and controlled or limited systemic disease may benefit from aggressive treatment as both qualities of life and survival are primarily related to the treatment of brain lesions.

Strong positive prognostic factors include good functional status, age <65 years, no sites of metastases outside of the central nervous system (CNS), and controlled primary tumor ²⁾, the presence of single metastasis in the brain, long interval from primary diagnosis to brain relapse, and certain cancer subtypes such as HER2-positive brain metastases and EGFR Non-Small cell lung cancer intracranial metastases ^{3) 4) 5)}.

Recursive partitioning analysis class

http://rcalc.ccf.org, under the category “Brain Cancer” ⁶⁾.

In a study of the Royal North Shore Hospital, on univariate analysis, number of metastases (P = 0.04), symptomatic extracranial disease (P = 0.04) and early CNS relapse within 6 months (P < 0.01) had worse survival. No grade 3-4 toxicity events were noted in 129 patients undergoing RT ⁷⁾.

It is presently unknown whether patients with brain metastases from heavily pre-treated cancers have a significantly different prognosis than those with less pre-treatment ⁸⁾.

Intracranial metastases recurrence